Source comparison
PT-141 Oral vs Injectable: Administration Comparison
The table below summarizes the pharmacokinetic, clinical, and practical differences between oral and injectable bremelanotide formulations based on published trial data and pharmacological modeling. Bioavailability <3% (extensive first-pass metabolism and GI d
This comparison does not assign a generated winner or score.
- The table below summarizes the pharmacokinetic, clinical, and practical differences between oral and injectable bremelanotide formulations based on published trial data and pharmacological modeling.
- Bioavailability
- <3% (extensive first-pass metabolism and GI degradation)
- 80–100% (bypasses hepatic first-pass)
- Injectable achieves therapeutic plasma levels; oral does not at tolerable doses
- Typical Dose
- 20–25mg attempted in trials (failed to achieve efficacy)
- 1.75mg (FDA-approved dose)
- Oral requires 10–15× higher dose with worse outcomes
- Time to Peak Plasma Concentration (Tmax)
- Highly variable, 90–180 min (if absorbed)
- 45–60 minutes
- Injectable provides predictable onset; oral is erratic
- Half-Life (T½)
- Not reliably measured (insufficient systemic exposure)
- ~2.7 hours
- Subcutaneous allows dose timing relative to activity
- Nausea Incidence
- >60% at 20–25mg oral
- ~40% at 1.75mg subcutaneous
- Lower dose via injection = better tolerability
- FDA Approval Status
- Not approved (discontinued from development)
- Approved June 2019 (Vyleesi)
- Only injectable formulation has regulatory backing
- Clinical Efficacy (HSDD trials)
- No published Phase 3 data showing efficacy
- Demonstrated significant improvement in SSEs and FSFI-desire (RECONNECT trial)
- Oral formulations did not meet endpoints
- Research Use Case
- Unsuitable for reproducible MC4R activation studies
- Standard for sexual pharmacology research
- Injectable is the only viable research tool
- The practical takeaway: oral PT-141 formulations marketed by compounding sources or research suppliers do not replicate the pharmacological profile of subcutaneous bremelanotide. Researchers requiring melanocortin receptor agonism for experimental protocols must specify injectable administration. Oral delivery introduces variability that cannot be controlled through dose adjustment. Our peptide synthesis process at Real Peptides ensures exact amino acid sequencing for subcutaneous formulations, which is the only route that consistently delivers the published clinical outcomes.